12th International Conference on HHV-6 & 7 Announced The 12th International Conference on HHV-6 & 7 will convene in Japan at the Himeji Culture and Convention Center in March 2025.
Short-course foscarnet at an early stage may suppress HHV-6 reactivation following allogenic HCT Observational study suggests that an early one-week treatment at the first sign of viral reactivation may achieve clinical benefits and avoid antiviral toxicity.
Herpesvirus Reactivation Common in Severe COVID-19 HHV-6 was the most common herpesvirus found when tested in nasal swabs, but EBV was the most common in plasma.
High levels of HHV-6A DNA found in blood of 52% of kidney transplant patients HHV-6A was the most common virus identified, but was not linked to worse outcomes compared to other viral infections.
